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Background: Breast tuberculosis (breast TB) is an extremely rare disease, so case reviews are also rare.
Methods: This study is a retrospective review of patients with breast TB who were treated between 2002 and 2012
at the Health Center of Gorgan City.
Results: All 22 patients were females, their mean age was 32.4 years, and all were new cases. Patients presented
with swelling of the breast (22%), lump (55%) and excretion from the involved breast (27%), and breast pain (55%).
The highest rate of breast TB occurred in 2011 (27%). All patients received the DOTS regimen for a mean duration
of 7.3 ± 0.7 months; in addition, segmental resection was performed on 11 patients (50%).
Conclusions: The findings confirmed that breast TB in Iran should be considered as a differential diagnosis of
breast masses. All patients in our study received the daily and ‘Directly Observed Treatment Short-course’ (DOTS)
regimens. Anti-tubercular therapy for six months with or without minimal surgical intervention currently is the
main treatment.
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The World Health Organization (WHO) estimated that
there were 8.7 million cases of tuberculosis (TB) in the
world in 2011, a rate of 125 cases per 100,000 people. It
also was estimated that there were 12 million prevalent
tuberculosis cases [1]. Breast TB was first defined by Sir
Astley Cooper in 1829 as a rare form of extrapulmonary
TB [2]. Breast TB is a very rare disease [3-5] and consti-
tutes only 0.025-1.04% of all breast diseases [6]. Its
prevalence has been estimated to be 0.1% of breast le-
sions examined histologically, and it constitutes about
3–4.5% of surgically-treated breast diseases in develop-
ing countries [7]. Despite the high prevalence of tuber-
culosis, mammary cells offer great resistance to the
survival and multiplication of mycobacterium tubercu-
losis [8]. The disease may be of primary etiology when
infection affects only the breast, or it may result from
other foci in the body, which is termed as secondary
breast TB. Presentation of breast TB is variable and may* Correspondence: mehravar10261@yahoo.com
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article, unless otherwise stated.be confused with other disorders [9,10]. Fine Needle As-
piration Cytology (FNAC) is the most extensively used
initial invasive method for diagnosis of breast TB
[11,12], and the ‘gold standard’ diagnostic tool for breast
TB is bacteriological culture of breast tissue or the
Ziehl–Neelsen stain [10]. Breast TB is often misdiag-
nosed as a pyogenic abscess or carcinoma of breast, both
clinically as well as radiologically, especially if well-
defined clinical features are absent [13]. In the present
study, our aim was to evaluate demographic data, diag-
nostic methods, and therapeutic regimens in 22 breast
TB patients treated at the Tuberculosis Control Health
Center in Gorgan, Iran over a period of 10 years.Methods
Over the 10-year period from 2002 through 2011, 22 pa-
tients were diagnosed with breast TB, and the patients
were referred to health centers in Gorgan City for the
‘Directly Observed Treatment Short-course’ (DOTS).
Gorgan is in the center of Golestan state in northern
Iran, just southeast of the Caspian Sea. Demographic
data, such as age, gender, weight at diagnosis, ethnicity,
location, occupation, marital status, educational status,BioMed Central Ltd. This is an Open Access article distributed under the terms
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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physical examination findings of the patient records
were documented.
The cytological findings of epithelioid cell granulomas,
Langhans’ giant cells, and lymphohistiocytic aggregates
confirmed the diagnosis. The discharge from the sinus
was subjected to Ziehl-Neelson staining and cultured for
acid fast bacilli. Sonography was performed for 77.2% of
the patients. Mammography was performed on three
patients (13.6%), and non-specific stromal coarsening
existed in all three patients. The chest radiographs of the
22 patients were normal. The diagnosis of breast TB was
confirmed by a combination of clinical suspicion and bi-
opsy findings. After primary diagnosis of patients by our
doctor, they were referred to a health center in Gorgan
and continued treatment as planned.
In 1978, according to the World Health Organization’s
(WHO’s) guideline [1], the Ministry of Health and Medical
Education of Iran effectively implemented the DOTS
strategy to fight tuberculosis. Based on the national strat-
egy of DOTS, new patients were treated with a short-term
diet for six months, followed by re-treatment with a regi-
men of eight months. Both regimens consisted of two
phases, i.e., attack and maintenance.
The DOTS regimen was put into practice in Gorgan
in June 1998. The records of the breast TB cases that
were treated between January 2002 and June 2012 were
reviewed. The breast TB regimens used in the health
centers in Gorgan City are presented in Table 1. In this
study, standard six-month anti-TB therapy (isoniazid, ri-
fampicin, pyrazinamide, and ethambutol) was commenced
with good clinical response. The continuation phase lasted
four months with isoniazid and rifampin on a daily basis
and the regime’s maintenance phase continued for an-
other three months.
Some patients had breast lumps that were potentially
malignant, and they also underwent segmental mastec-
tomy. Residual lumps after anti-tubercular therapy
(ATT) may require surgical removal. Minimal surgical
intervention was required for drainage of abscesses of
the breast or taking biopsies from the wall of the ab-
scess, scraping of sinuses in the breast, and incisional or
excisional biopsy.Table 1 Breast TB treatment regimens [11]
Treatment time Initial phase regimens Continuation
phase regimens
6 months 2 months of isoniazid,
rifampycine, pyrazinamide,
ethambutol or streptomycin
4 months of isoniazid
and rifampycine
9 months 2 months of isoniazid,
rifampycine, pyrazinamide,
ethambutol or streptomycin
7 months of Isoniazid
and rifampycineThis study obtained ethics approval and was approved
by Ethical Committee of Golestan University of Medical
Science.
Statistical analysis
Data relating to the duration of therapy and to whether
DOTS was administered were recorded with SPSS ver-
sion 16.0. Descriptive analyses were performed to detect
differences between subgroups.
Results
In this study, 22 known breast TB cases were identified,
and all the patients were female. The mean age of the pa-
tients was 32.4 (range 23–66). All of the patients were new
cases. Among the patients, 15 were of reproductive age,
and one of the 15 was pregnant at the time of diagnosis.
Patients presented with swelling of the breast (22%),
lump (55%) and excretion from the involved breast (27%),
and breast pain (55%). The left side of the breast was in-
volved in 16 cases, and the right side of the breast was
involved in 4 cases. The disease was bilateral in two pa-
tients. Most of the patients (59.09%) were from urban
areas, and most were of Persian ethnicity (68.18%), as
summarized in Table 2. The highest rate of breast TB was
seen in 2011 (27%).
Sonography was conducted for 17 patients, and a de-
fined breast lump was found in 13 patients (55%); de-
fined isolateral auxiliary lymph node involvement was
observed in seven patients (31.8%); defined non-specific
findings were made in five patients (18.5%), including
hypoechoic masses, internal echoes, and irregular bor-
ders; and bilateral auxiliary lymph node involvement was
observed in one patient (3.7%). Mammography was per-
formed on three patients (13.6%), and the results showed
non-specific stromal coarsening in all three patients.
The most frequently used diagnostic tool was excisional
biopsy (81.81%) and positive TB culture (9.09%). The
breast TB diagnostic criteria for this study were based
on biopsy and clinical response. Histopathology of the
specimen (lump) findings included epitheloid cell granu-
lomas without caseous necrosis.
Eleven patients underwent segmental mastectomy
and anti-tuberculosis drug therapy, and another eleven
patients underwent just anti-tuberculosis drug therapy
after fine-needle aspiration. All patients completed ther-
apy with a full recovery. Our treatment success rate was
100%. A six-month treatment regimen was administered
to all patients, but for some patients (n = 4) that had a
fistula and abscess, the regime was nine months.
Twenty-two patients received the DOTS regimen for a
mean duration of 7.3 ± 0.7 months; in addition, seg-
mental resection was performed on 11 patients (50%),
and two patients underwent complementary surgery for
drainage of abscesses.
